Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.
Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.
复制标题
放射性标记肿瘤相关抗体的放射性核素选择和模型吸收剂量计算。
DOI：
10.1118/1.595559
复制
发表时间：
1984
期刊：
影响因子：
3.8
通讯作者：
R. Rogus
中科院分区：
文献类型：
--
作者：
B. Wessels;R. Rogus
计算了分布在标准几何形状和肿瘤位置上的放射性标记肿瘤相关抗体的吸收剂量计算比较。编制了9种放射性核素的半衰期、最大比活度和相对器官剂量数据，其中的9种放射性核素是假定这些放射性核素与抗体偶联的。这些核素是根据物理特性选择的，这些特性保证了它们作为成像或治疗放射性标记被包括在内。放射性核素的生物分布数据基于目前对人体抗体摄取和清除的现有估计而被采用。Re-186和Y-90已被确定为最好的治疗放射性标记之一，因为它们具有足够长的肿瘤定位所需的半衰期，很少或没有伽马辐射，中等的β能量，稳定的子产物，并有合理的机会与抗体系统形成稳定的螯合物。
An absorbed dose calculation comparison has been computed for radiolabeled tumor associated antibodies distributed over a standard geometry and tumor location. Half-life data, maximum specific activities, and relative organ doses of nine radionuclides, Cu-67, Br-77, Br-82, Y-90, Tc-99m, In-111, I-131, Re-186, and At-211, have been compiled in which the radionuclides were assumed to be coupled with antibody. These nuclides were chosen on the basis of physical characteristics that warranted their inclusion as either imaging or therapy radiolabels. Radionuclide biodistribution data based on current available estimates for antibody uptake and clearance in humans has been adopted. Re-186 and Y-90 have been determined to be among the best therapy radiolabels since they possess sufficiently long half lives necessary for tumor localization, little or no gamma radiation, intermediate beta energy, stable daughter products, and have a reasonable chance to form a stable chelate with an antibody system.